<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628081</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9174-SG-CTIL</org_study_id>
    <nct_id>NCT01628081</nct_id>
  </id_info>
  <brief_title>The Effect of Alga Dunaliella Bardawil on Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, parallel group, randomized study with 12 weeks of daily oral&#xD;
      administration of Dunaliella or placebo in psoriasis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened for eligibility at the baseline visit for blood tests.&#xD;
&#xD;
      After screen phase of maximum two weeks the subjects will be randomized to one of two&#xD;
      treatments groups (1:1): Dunaliella or placebo.&#xD;
&#xD;
      Each subject will have a final evaluation 4 weeks after the end of study drug treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline (predose day 1) to 18-week period Target Lesion Severity score (TLS) of lesions</measure>
    <time_frame>Subjects will have study visits at screening- visit 1, randomization - visit 2, after 6 weeks treatment - visit 3, 12 weeks treatment -end of treatment - visit 4 and week 16 - follow up visit 5.</time_frame>
    <description>Target lesions will be evaluated for 3 components: erythema, induration, and scaling. Each component will be given a score using the following scale: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The Target Lesion Severity (TLS) score is calculated as a sum of the 3 components.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Alga Dunaliella bardawil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage Regimen and Treatment Groups&#xD;
Daily oral administration of:&#xD;
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).&#xD;
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alga Dunaliella Bardawil placebo</intervention_name>
    <description>Dosage Regimen and Treatment Groups&#xD;
Daily oral administration of:&#xD;
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).&#xD;
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dunaliella Bardawil</intervention_name>
    <description>Dosage Regimen and Treatment Groups&#xD;
Daily oral administration of:&#xD;
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).&#xD;
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).</description>
    <arm_group_label>Alga Dunaliella bardawil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, ≥ 18 to ≤ 75 years of age, who have a diagnosis of plaque or&#xD;
             guttate psoriasis;&#xD;
&#xD;
          -  Psoriasis covering ≤ 20% of body surface area (BSA)&#xD;
&#xD;
          -  Have at least 2 psoriatic plaques measuring 3 cm or more.&#xD;
&#xD;
          -  For a female subject; either:&#xD;
&#xD;
          -  subject is non-childbearing potential, defined as: menopause with amenorrhea &gt; 2&#xD;
             years, hysterectomy, or bilateral oophorectomy or&#xD;
&#xD;
          -  agrees to continue to use adequate contraception (i.e., hormonal [oral, depot, patch],&#xD;
             IUD, barrier and spermicide) throughout the study and for at least one month following&#xD;
             termination and have a negative urinary pregnancy test at screening and before the&#xD;
             first dose of study drug;&#xD;
&#xD;
          -  In the opinion of the Investigator, the subject will be compliant and have a high&#xD;
             probability of completing the study and all required procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject presents with the predominant type of psoriasis as erythrodermic, inverse,&#xD;
             pustular or palmo-plantar or an unstable form of psoriasis;&#xD;
&#xD;
          -  Received any investigational drug within 30 days of randomization.&#xD;
&#xD;
          -  The subject has not used the following psoriasis treatment for the elaborated periods,&#xD;
             prior to the date of screening visit:&#xD;
&#xD;
        Topical psoriasis treatment, excluding emollients 2-week period Any systemic psoriasis&#xD;
        treatment including biologic treatments 4-week or 5-half life time periods (whichever is&#xD;
        longer) Phototherapy or Climatotherapy 4-week period&#xD;
&#xD;
          -  The subject has a known allergy or sensitivity to the study treatment(s) or to any of&#xD;
             the percipient contained in the study drug formulation&#xD;
&#xD;
          -  Any other acute or chronic medical condition that, in the opinion of the Investigator,&#xD;
             increases the risk to the subject or the likelihood that the subject will be unable to&#xD;
             complete the study;&#xD;
&#xD;
          -  Subjects with any laboratory test at screening considered significantly abnormal.&#xD;
&#xD;
        The following will be considered significantly abnormal:&#xD;
&#xD;
        Alanine transaminase (ALT), aspartate transaminase (AST) &gt; 3 upper limit normal. CPK &gt; 3&#xD;
        upper limit normal. Triglycerides &gt; 350mg/dl.&#xD;
&#xD;
        cytopenia (to include any of the following: WBC &lt; 35000/μL; Hgb &lt; 10 g/dL; platelets&#xD;
        &lt;120,000/μL; neutrophils absolute &lt; 1500/μL lymphocytes absolute &lt; 800/μL) or&#xD;
&#xD;
          -  Known serologic positively for human immunodeficiency virus or hepatitis B or&#xD;
             hepatitis C virus.&#xD;
&#xD;
          -  History of substance abuse, including alcohol abuse, within the past year.&#xD;
&#xD;
          -  History or current clinically significant major psychiatric disorder (e.g., major&#xD;
             depressive disorder, psychosis, schizophrenia) according to the criteria of the&#xD;
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV TR)&#xD;
             [Exception; subjects with depression that has been adequately controlled for at least&#xD;
             6 months may enroll in the study];&#xD;
&#xD;
          -  Female subject with a positive pregnancy test or nursing, or planning a pregnancy&#xD;
             during the course of the study;&#xD;
&#xD;
          -  Unwilling or unable to comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoshana Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamar Luvish, BSN</last_name>
    <phone>972-35303492</phone>
    <email>tamar.luvish@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Bert W. Strassburger Lipid Center,Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shoshna Greenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Bert W. Strassburger Lipid Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ofir Artzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>Alga Dunaliella Bardawil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

